Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Clin. transl. oncol. (Print) ; 19(3): 291-300, mar. 2017. graf
Article in English | IBECS | ID: ibc-160185

ABSTRACT

The coming into force of Directive 2001/20/EC represented a step forward in harmonising clinical trial regulation in European countries, guaranteeing a uniform protection of subjects participating in clinical research across Europe. However, it led to a disproportionate increase in the bureaucratization, and thus, it became evident that procedures needed to be simplified without detriment to patient’s safety. Thus, Regulation 536/2014, that repealed Directive 2001/20/EC, with the aim of decreasing the growing bureaucratization and stimulating clinical research in Europe, established simplified procedures, such as regulating a common procedure for authorising trials in Europe, the institution of strict assessment timelines, or the definition of new concepts, such as «low-intervention clinical trial». The legal form of a Regulation allowed the norm to be directly applied to Member States without the need for transposition. By means of the new Royal Decree, the national legislation is adapted to make the application of the regulation feasible and it allows the development of the aspects that the Regulation leaves to national legislation. Both documents seek to stimulate clinical research with medicinal products to foster knowledge, facilitate transparency, and reinforce subjects’ safety. This will surely be the case, but with this revision, we will look at the novelties and key aspects that are most relevant to investigators and we will analyse the consequences for all parties involved in clinical research (AU)


No disponible


Subject(s)
Humans , Male , Female , Clinical Trials as Topic/legislation & jurisprudence , Patient Freedom of Choice Laws/standards , Legal Intervention , Controlled Before-After Studies/legislation & jurisprudence , Compensation and Redress/legislation & jurisprudence , 51725/legislation & jurisprudence , Biomedical Research/legislation & jurisprudence , Clinical Trials Data Monitoring Committees/legislation & jurisprudence , Health Care Coordination and Monitoring , Helsinki Declaration , European Union/organization & administration
2.
Clin. transl. oncol. (Print) ; 11(11): 727-736, nov. 2009. tab, ilus
Article in English | IBECS | ID: ibc-123703

ABSTRACT

Treatment of anaemia is a very important aspect in the management of cancer patients. In order to carry out a consensus process about the use of erythropoietic stimulating agents (ESAs) in cancer patients, the Spanish Society of Medical Oncology (SEOM) elaborated a working group which coordinated a panel of medical oncology specialists. This working group has reviewed the main issues about the use of ESAs. In addition a consensus meeting was held in Madrid on 25 April 2007. The following conclusions were made: Since ESA treatment increases the haemoglobin (Hb) level and decreases the red blood cell (RBC) transfusion requirements, ESAs should be used within the approved indications in patients undergoing chemotherapy treatment, beginning at a Hb level below 11 g/dl and maintaining it around 12 g/dl, with iron supplements if necessary. Neither increasing the ESA dose in nonresponders nor the use of ESAs in the treatment of chronic cancer-related anaemia is recommended (AU)


No disponible


Subject(s)
Humans , Male , Female , Anemia/complications , Anemia/drug therapy , Hematinics/metabolism , Hematinics/therapeutic use , Medical Oncology/methods , Neoplasms/complications , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Blood Transfusion , Chronic Disease/drug therapy , Clinical Trials as Topic/methods , Clinical Trials as Topic , Erythrocytes/metabolism , Hemoglobins/metabolism , Iron/metabolism , Spain/epidemiology
3.
Clin. transl. oncol. (Print) ; 9(9): 582-589, sept. 2007.
Article in English | IBECS | ID: ibc-123360

ABSTRACT

At present, anaemia in the patients with cancer remains a problem of the first magnitude and of increasing interest due to the high incidence, the major knowledge of its physiopathology, the negative impact on the quality of life of the patient, the influence on the evolution of the disease and its treatments and, finally to the progressive development of new alternatives of treatment, especially the erythropoietic agents. For all this, it becomes necessary to consider the treatment of the anemia of the patients with cancer as a basic part of their support treatment. The erythropoietic agents have demonstrated in the last years that constitute a therapeutic alternative to obtain an increase of the levels of hemoglobin in the patients with anticancer treatments, considering specially that the correction of the anemia not only represents the improvement of an analytical value but also has a significant impact on the quality of life of the patients and diminishes the transfusion requirements. Erythropoietic proteins available for the treatment of the anemia of the patients with cancer are Epoetin-alpha, Epoetin-beta and Darbepoetin-alpha. The existence of different drugs, different doses and intervals of administration, clinical different situations and heterogeneous studies, made necessary the development of documents of consensus and guides of clinical recommendations which provide information on the scientific evidence that supports the use of these agents in medical care. This paper summarizes the main recommendations from panels of experts and scientific societies published so far (AU)


Subject(s)
Humans , Male , Female , Anemia/drug therapy , Hematinics/therapeutic use , Erythropoietin/therapeutic use , Neoplasms/complications , Neoplasms/drug therapy , Societies, Scientific/legislation & jurisprudence , Anemia/etiology , Antibiotics, Antineoplastic/adverse effects , Neoplasms/metabolism , Societies, Scientific/organization & administration , Societies, Scientific/standards
SELECTION OF CITATIONS
SEARCH DETAIL
...